Goaded by Tariffs, European Pharmaceutical Industry Pivots to the US

Contact Your Elected Officials

Analysts say drugmakers wouldn’t risk a disadvantage in the United States, the world’s biggest economy and pharmaceutical market.

The U.S. tariff policy and its unmatched pharmaceutical market are pulling European drugmakers to invest more heavily, from new manufacturing plants to U.S. stock listings and discount pricing deals.

Since early 2025, European drugmakers have stepped up their U.S. presence. In the most recent move, the United Kingdom’s giant AstraZeneca announced on Sept. 29 a direct listing on the New York Stock Exchange, just months after pledging $50 billion of U.S. investment by 2030.

The UK-headquartered Indivior dropped its London listing in July to trade solely on Nasdaq, while Swiss giants Roche and Novartis unveiled U.S. expansion plans in April worth $23 billion and $50 billion, respectively. France’s Sanofi has likewise committed at least $20 billion in American projects through 2030.

The moves reflect both the pull of the U.S. market, which accounted for more than half of global prescription medicine sales in 2024, and the push of political signals from Washington.

On Sept. 25, President Donald Trump, after months of warning about pharmaceutical tariffs, announced a 100 percent levy on imports of branded and patented medicines from Oct. 1 unless manufacturers build plants in the United States.

“Pharmaceutical companies are very cognizant of what the White House is saying, and they’re acting accordingly,” Russ Mould, investment director at British investment platform AJ Bell, told The Epoch Times.

He said that the United States, as the world’s largest economy and the biggest pharmaceutical market, was not a place where any chief executive wanted to risk being put at a competitive disadvantage.

US Market Dwarfs Its Peers

According to data from the European Federation of Pharmaceutical Industries and Associations (EFPIA), North America represented 54.8 percent of global prescription sales in 2024, compared with 22.7 percent for Europe.

Between 2019 and 2023, two-thirds of new drug launches were made first in the United States, compared with just 16 percent across Europe’s top five markets.

That dominance has left non-U.S. drugmakers highly exposed to tariff risk. The European Union exported nearly €120 billion ($127 billion) worth of medicines to the United States in 2024, making America its largest pharmaceutical trading partner, according to the European Commission.

The United Kingdom alone shipped £7 billion ($8.5 billion) in pharmaceutical products across the Atlantic in the year to March 2025, UK government data show.

Industry analysts say the U.S. tariff policy, combined with Trump’s push for lower U.S. drug prices, are accelerating strategic shifts.

“It does look as though it is the direction of travel,” said Susannah Streeter, money and markets analyst at UK consultancy Consultable told The Epoch Times. “If companies are planning to build a factory in the United States, they will be exempt from extra tariffs. So this is concentrating minds among pharma giants about where to locate future manufacturing facilities.”

By Evgenia Filimianova

Read Full Article on TheEpochTimes.com

The Epoch Times
The Epoch Timeshttps://www.theepochtimes.com/
Tired of biased news? The Epoch Times is truthful, factual news that other media outlets don't report. No spin. No agenda. Just honest journalism like it used to be.

Hamas’s Stubborn Grip on Arms Signals No Desire for Genuine Peace

Hamas’s rhetoric reflects its founding ideology, prioritizing armed resistance over civilian welfare or diplomatic progress.

Off the radar

In the longstanding and brutal ledger of religious persecution, Nigeria now occupies its own grim chapter with its enduring pogrom against Christians.

The New Jackboots? A Wake-Up Call on Antifa and Fascism

An analysis of whether Antifa truly opposes fascism by comparing its tactics and behavior to historical signs and movements of fascist regimes.

If Federal Food Assistance Programs End, Theft Begins

Many patriotic Americans well versed in American History have...

Tucker EN FUEGO: Taking Stock of MAGA, Ten Years on

Draining of the Swamp has yet to come anything close to fruition, as the creatures that populate said Swamp yet cling bitterly to power.

Dallas Doctor Surrenders License After Texas AG Sues for Prescribing Gender Transition Drugs to Minors

Doctor surrendered her medical license following lawsuit by Texas AG Paxton, accusing her of illegally prescribing gender transition drugs to minors.

June Lockhart, Beloved Mother Figure From ‘Lassie’ and ‘Lost in Space,’ Dies at 100

June Lockhart, a mother figure for a generation of TV viewers whether at home in “Lassie” or in the stratosphere in “Lost in Space,” has died at 100.

Kamala Harris Teases New White House Run: ‘I Am Not Done’

Kamala Harris hinted in a BBC interview that she may run for president again in 2028, saying she hasn’t ruled out another White House bid.

TCM Classic Tour at Warner Bros. Studio: Finding Stardust in Today’s Hollywood

Warner Bros. launched the TCM Classic Films Tour in April 2024, offering visitors a nostalgic journey through the studio’s historic movie legacy.

Trump Hikes Canada’s Tariffs by 10 Percent for Not Pulling Anti-Tariff Ad Immediately

Trump announced he will increase tariffs on Canada by 10% after ad by provincial government of Ontario misrepresented President Reagan’s speech on tariffs.

Trump Rolls Back Emissions Rules on Copper Smelters

President Trump issued a proclamation aimed at reversing a Biden-era environmental rule that enforced stricter air emission standards on copper smelters.

Donor Gives $130 Million to Cover Shortfall in Troop Pay During Shutdown

Trump announced on Oct. 23 that an anonymous donor sent $130M to cover military pay during the ongoing government shutdown.

‘Frustration’ With Canada Led to Trump Scrapping Talks, Not Just Ontario’s Ad: US Official

President Trump cited Ontario’s TV ad as the reason for halting Canada trade talks, but officials say it stems from rising U.S. frustration with Ottawa.
spot_img

Related Articles

Popular Categories

MAGA Business Central